Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: Development and validation of sensitive BCR::ABL1 fusion gene quantitation using next-generation sequencing

Fig. 3

Monitoring of chronic myeloid leukemia patients during TKI treatment. (A) BCR::ABL1 log reduction trend measured with NGS in samples from 37 patients who underwent follow-up tests during TKI therapy from the time of diagnosis. (B) Comparison of MR values of NGS and RQ-PCR according to post-treatment time points up to 12 months in serial samples. MR: molecular response; MMR: major molecular response; DMR: deep molecular response; ND: not detected; TKI: tyrosine-kinase inhibitor

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us